MGNX - MacroGenics' flotetuzumab shows positive effect in leukemia study

MacroGenics (MGNX) announces encouraging preliminary data from a Phase 1/2 clinical trial evaluating flotetuzumab in acute myeloid leukemia ((AML)) patients. The results were just published in the journal Blood.In a subset of patients high poor prognoses and high unmet medical needs, the complete remission rate was 16.7% (n=5/30) while the complete remission rate with partial hematologic recovery was 26.7% (n=8/30) following treatment with flotetuzumab.Additional data from the trial should be available later this year.Flotetuzumab (MGD006) is a bispecific DART molecule that recognizes both CD123 on leukemic cells and CD3 on T cells, with the intended result of T cell-mediated killing of leukemic blasts.The company regained the rights to the candidate from Laboratoires Servier earlier this year.

For further details see:

MacroGenics' flotetuzumab shows positive effect in leukemia study